肺癌诊断与临床分期中肿瘤标志物检测的价值探究

The Value of Tumor Marker Detection in Diagnosis and Staging of Lung Cancer

目的分析肺癌诊断与临床分期中肿瘤标志物检测的临床价值。方法选取2014年8月-2016年4月在我院进行就诊的患者120例,将120例患者分为肺癌组和良性病变组,肺癌组不包含良性病变患者,也不包含其他系统性疾病。对两组人员均实施肿瘤标志物检测,分析肿瘤标志物在肺癌诊断与临床分期中的应用价值。结果肺癌疾病组患者的NSE水平与CEA水平高于良性疾病组,且两组在数据差异方面进行观察,差异有统计意义（P〈0.05）。结论肿瘤标志物对肺癌早期诊断具有重要家孩子,可以有效提高对肺癌疾病的诊断灵敏度,对患者的病情严重程度的判定提供重要的参考数据。

Objective To analyze the clinical value of tumor markers in the diagnosis and staging of lung cancer. Methods From August 2014 to April 2016, in our hospital for treatment of 120 patients, 120 patients were divided into lung cancer group and benign lesion group, lung cancer group does not include patients with benign lesions, and does not contain other systemic diseases. The tumor markers were detected in the two groups, and the value of tumor markers in the diagnosis and clinical staging of lung cancer was analyzed. Results The level of NSE and CEA in patients with lung cancer were higher than those in benign disease group, and the difference between two groups was statistically significant（P0.05）. Conclusion Tumor markers for early diagnosis of lung cancer has an important child, can effectively improve the diagnostic sensitivity of lung cancer, to provide an important reference data to determine the severity of the patient＇s condition.